Heikki Joensuu1, Pirkko-Liisa Kellokumpu-Lehtinen2, Riikka Huovinen3, Arja Jukkola2,4, Minna Tanner2, Johan Ahlgren5,6, Päivi Auvinen7, Outi Lahdenperä3, Kenneth Villman8, Paul Nyandoto9, Greger Nilsson10, Paula Poikonen-Saksela1, Vesa Kataja11, Petri Bono1, Jouni Junnila12, Henrik Lindman13. 1. Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. 2. Department of Oncology, Tampere University Hospital and Tampere University, Tampere, Finland. 3. Department of Oncology, Turku University Hospital, Turku, Finland. 4. Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland. 5. Gävle Hospital, Gävle, Sweden. 6. Regional Cancer Centre of Mid-Sweden, Academic Hospital, Uppsala, Sweden. 7. Cancer Center, Kuopio University Hospital, Kuopio, Finland. 8. Örebro University Hospital, Örebro, Sweden. 9. Päijät-Häme Central Hospital, Lahti, Finland. 10. Department of Oncology, Gävle Hospital and Visby Hospital, and Uppsala University, Uppsala, Sweden. 11. Central Finland Central Hospital, Jyväskylä, Finland. 12. EstiMates, Turku, Finland. 13. Department of Immunology, Genetics and Pathology, Uppsala University Hospital, Uppsala, Sweden.
Abstract
PURPOSE: Few data are available regarding the influence of adjuvant capecitabine on long-term survival of patients with early breast cancer. METHODS: The Finland Capecitabine Trial (FinXX) is a randomized, open-label, multicenter trial that evaluates integration of capecitabine to an adjuvant chemotherapy regimen containing a taxane and an anthracycline for the treatment of early breast cancer. Between January 27, 2004, and May 29, 2007, 1,500 patients with axillary node-positive or high-risk node-negative early breast cancer were accrued. The patients were randomly allocated to either TX-CEX, consisting of three cycles of docetaxel (T) plus capecitabine (X) followed by three cycles of cyclophosphamide, epirubicin, and capecitabine (CEX, 753 patients), or to T-CEF, consisting of three cycles of docetaxel followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (CEF, 747 patients). We performed a protocol-scheduled analysis of overall survival on the basis of approximately 15-year follow-up of the patients. RESULTS: The data collection was locked on December 31, 2020. By this date, the median follow-up time of the patients alive was 15.3 years (interquartile range, 14.5-16.1 years) in the TX-CEX group and 15.4 years (interquartile range, 14.8-16.0 years) in the T-CEF group. Patients assigned to TX-CEX survived longer than those assigned to T-CEF (hazard ratio 0.81; 95% CI, 0.66 to 0.99; P = .037). The 15-year survival rate was 77.6% in the TX-CEX group and 73.3% in the T-CEF group. In exploratory subgroup analyses, patients with estrogen receptor-negative cancer and those with triple-negative cancer treated with TX-CEX tended to live longer than those treated with T-CEF. CONCLUSION: Addition of capecitabine to a chemotherapy regimen that contained docetaxel, epirubicin, and cyclophosphamide prolonged the survival of patients with early breast cancer.
PURPOSE: Few data are available regarding the influence of adjuvant capecitabine on long-term survival of patients with early breast cancer. METHODS: The Finland Capecitabine Trial (FinXX) is a randomized, open-label, multicenter trial that evaluates integration of capecitabine to an adjuvant chemotherapy regimen containing a taxane and an anthracycline for the treatment of early breast cancer. Between January 27, 2004, and May 29, 2007, 1,500 patients with axillary node-positive or high-risk node-negative early breast cancer were accrued. The patients were randomly allocated to either TX-CEX, consisting of three cycles of docetaxel (T) plus capecitabine (X) followed by three cycles of cyclophosphamide, epirubicin, and capecitabine (CEX, 753 patients), or to T-CEF, consisting of three cycles of docetaxel followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (CEF, 747 patients). We performed a protocol-scheduled analysis of overall survival on the basis of approximately 15-year follow-up of the patients. RESULTS: The data collection was locked on December 31, 2020. By this date, the median follow-up time of the patients alive was 15.3 years (interquartile range, 14.5-16.1 years) in the TX-CEX group and 15.4 years (interquartile range, 14.8-16.0 years) in the T-CEF group. Patients assigned to TX-CEX survived longer than those assigned to T-CEF (hazard ratio 0.81; 95% CI, 0.66 to 0.99; P = .037). The 15-year survival rate was 77.6% in the TX-CEX group and 73.3% in the T-CEF group. In exploratory subgroup analyses, patients with estrogen receptor-negative cancer and those with triple-negative cancer treated with TX-CEX tended to live longer than those treated with T-CEF. CONCLUSION: Addition of capecitabine to a chemotherapy regimen that contained docetaxel, epirubicin, and cyclophosphamide prolonged the survival of patients with early breast cancer.
Authors: F Cardoso; S Kyriakides; S Ohno; F Penault-Llorca; P Poortmans; I T Rubio; S Zackrisson; E Senkus Journal: Ann Oncol Date: 2019-10-01 Impact factor: 32.976
Authors: Gunter von Minckwitz; Bettina Conrad; Toralf Reimer; Thomas Decker; Holger Eidtmann; Wolfgang Eiermann; John Hackmann; Volker Möbus; Frederik Marmé; Jochem Potenberg; Elmar Stickeler; Eike Simon; Christoph Thomssen; Jens Huober; Carsten Denkert; Joachim Alfer; Christian Jackisch; Valentina Nekljudova; Nicole Burchardi; Sibylle Loibl Journal: Cancer Date: 2015-06-25 Impact factor: 6.860
Authors: Hyman B Muss; Mei-Yin C Polley; Donald A Berry; Heshan Liu; Constance T Cirrincione; Maria Theodoulou; Ann M Mauer; Alice B Kornblith; Ann H Partridge; Lynn G Dressler; Harvey J Cohen; Patricia A Kartcheske; Edith A Perez; Antonio C Wolff; Julie R Gralow; Harold J Burstein; Ahmad A Mahmood; Linda M Sutton; Gustav Magrinat; Barbara A Parker; Ronald D Hart; Debjani Grenier; Arti Hurria; Aminah Jatoi; Larry Norton; Clifford A Hudis; Eric P Winer; Lisa Carey Journal: J Clin Oncol Date: 2019-07-24 Impact factor: 44.544
Authors: V Möbus; G von Minckwitz; C Jackisch; H-J Lück; A Schneeweiss; H Tesch; D Elling; N Harbeck; B Conrad; T Fehm; J Huober; V Müller; I Bauerfeind; A du Bois; S Loibl; V Nekljudova; M Untch; C Thomssen Journal: Ann Oncol Date: 2017-08-01 Impact factor: 32.976
Authors: R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard Journal: Lancet Date: 2011-12-05 Impact factor: 79.321
Authors: Jyothi S Prabhu; Aruna Korlimarla; Krisha Desai; Annie Alexander; Rohini Raghavan; Ce Anupama; Nandini Dendukuri; Suraj Manjunath; Marjorrie Correa; N Raman; Anjali Kalamdani; Msn Prasad; K S Gopinath; B S Srinath; T S Sridhar Journal: J Cancer Date: 2014-01-23 Impact factor: 4.207
Authors: Ingrid A Mayer; Fengmin Zhao; Carlos L Arteaga; William F Symmans; Ben H Park; Brian L Burnette; Amye J Tevaarwerk; Sofia F Garcia; Karen L Smith; Della F Makower; Margaret Block; Kimberly A Morley; Chirag R Jani; Craig Mescher; Shabana J Dewani; Bernard Tawfik; Lisa E Flaum; Erica L Mayer; William M Sikov; Eve T Rodler; Lynne I Wagner; Angela M DeMichele; Joseph A Sparano; Antonio C Wolff; Kathy D Miller Journal: J Clin Oncol Date: 2021-06-06 Impact factor: 50.717